Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms

NCT06974058 | Completed DMC

• 1 other identifier: LUMHS/REC/-735/13.05.2025
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

This pragmatic clinical study aims to evaluate the efficacy and tolerance of a combined quercetin/curcumin supplement in adults experiencing mild to moderate symptoms of Long COVID-19. Participants will receive the combined quercetin/curcumin supplement for 2 months. The primary outcome is the improvement in overall symptom burden, while secondary outcomes include changes in quality of life, the need for NSAIDs, and inflammatory markers. The study seeks to provide real-world evidence of the potential benefits of this combined supplement in managing Long COVID-19 symptoms.

Conditions

Long COVID

Outcome Measures

Primary Outcomes (1)

• Change in Overall Symptom Burden

  Assessment of overall symptom burden using the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS). Improvement will be defined as either a ≥2-point reduction in any single symptom domain or a ≥10% reduction in the total C19-YRS symptom burden score from baseline.

  8 weeks

Secondary Outcomes (7)

• Change in Functional Status and Quality of Life (SF-36 Scores)

  8 weeks

• Change in the Need for Prescribed Medications or NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

  8 weeks

• Change in Pain Severity and Pain Interference (Brief Pain Inventory - Short Form)

  8 weeks

• Change in Fatigue Severity (Fatigue Severity Scale)

  8 weeks

• Change in Anxiety and Depression Symptoms (Hospital Anxiety and Depression Scale)

  8 weeks

Study Arms (1)

Nasafytol® Group (Quercetin/Curcumin Supplement Group)

EXPERIMENTAL

Participants in this group will receive a combined supplement of Nasafytol®, containing quercetin (65 mg) and curcumin (42 mg). Participants will be instructed to take two capsules (single administration) twice a day for 8 weeks.

Dietary Supplement: Nasafytol® (Quercetin/Curcumin Supplement)

Interventions

Nasafytol® (Quercetin/Curcumin Supplement) DIETARY_SUPPLEMENT

Participants in this group will receive Nasafytol®, a combined dietary supplement containing quercetin (65 mg) and curcumin (42 mg). Participants will take two capsules (single administration) twice a day for a duration of 8 weeks. The supplement is intended to alleviate mild to moderate symptoms of Long COVID-19, including but not limited to fatigue, cognitive function, generalized body pain, low mood, sleep disturbance, and overall quality of life.

Nasafytol® Group (Quercetin/Curcumin Supplement Group)

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: 18 to 75 years.
• History of confirmed COVID-19 infection at least 6 months prior to the enrollment.
• Persistent mild to moderate COVID-19 symptoms for at least 3 months post-acute infection.
• Diagnosis of Long COVID-19 based on WHO criteria.
• Symptom burden score of ≥25 at baseline (V0) on the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS).
• At least one symptom scoring between 1-7 on the C19-YRS.
• Stable medical condition: No recent hospitalization (past 3 months) due to acute illness.
• Willing and able to adhere to the study protocol, including follow-up visits, symptom reporting, and compliance with supplementation

You may not qualify if:

• Hypersensitivity or allergy to quercetin, curcumin, or any component of the supplement (Nasafytol®).
• Severe, uncontrolled chronic illness (e.g., severe heart failure, chronic kidney disease requiring dialysis, severe liver disease).
• Regular use of quercetin or curcumin supplements within the last 3 months.
• Use of anticoagulants (e.g., warfarin, heparin, DOACs) due to potential anticoagulant effects of quercetin/curcumin.
• Acute illness at the time of screening.
• Pregnancy or breastfeeding.
• Use of immunosuppressive medications or corticosteroids within the past month.
• Significant psychiatric disorder that may interfere with study compliance.

Sponsors & Collaborators

• Liaquat University of Medical & Health Sciences: lead

Study Sites (1)

Liaquat University of Medical & Health Sciences (LUMHS)

Jamshoro, Sindh, 76090, Pakistan

Location

Related Publications (6)

• Vollbracht C, Kraft K. Oxidative Stress and Hyper-Inflammation as Major Drivers of Severe COVID-19 and Long COVID: Implications for the Benefit of High-Dose Intravenous Vitamin C. Front Pharmacol. 2022 Apr 29;13:899198. doi: 10.3389/fphar.2022.899198. eCollection 2022.

  PMID: 35571085 BACKGROUND

• Vlaming-van Eijk LE, Bulthuis MLC, van der Gun BTF, Wold KI, Veloo ACM, Vincenti Gonzalez MF, de Borst MH, den Dunnen WFA, Hillebrands JL, van Goor H, Tami A, Bourgonje AR. Systemic oxidative stress associates with the development of post-COVID-19 syndrome in non-hospitalized individuals. Redox Biol. 2024 Oct;76:103310. doi: 10.1016/j.redox.2024.103310. Epub 2024 Aug 19.

  PMID: 39163767 BACKGROUND

• Al-Hakeim HK, Al-Rubaye HT, Al-Hadrawi DS, Almulla AF, Maes M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: a proof of concept and mechanism study. Mol Psychiatry. 2023 Feb;28(2):564-578. doi: 10.1038/s41380-022-01836-9. Epub 2022 Oct 24.

  PMID: 36280755 BACKGROUND

• Gerain J, Uebelhoer M, Costes B, Herman J, Pietri S, Donneau AF, Monseur J, Henrotin Y. NASAFYTOL(R) supplementation in adults hospitalized with COVID-19 infection: results from an exploratory open-label randomized controlled trial. Front Nutr. 2023 Jun 22;10:1137407. doi: 10.3389/fnut.2023.1137407. eCollection 2023.

  PMID: 37426178 BACKGROUND

• Khan A, Iqtadar S, Mumtaz SU, Heinrich M, Pascual-Figal DA, Livingstone S, Abaidullah S. Oral Co-Supplementation of Curcumin, Quercetin, and Vitamin D3 as an Adjuvant Therapy for Mild to Moderate Symptoms of COVID-19-Results From a Pilot Open-Label, Randomized Controlled Trial. Front Pharmacol. 2022 Jun 7;13:898062. doi: 10.3389/fphar.2022.898062. eCollection 2022.

  PMID: 35747751 BACKGROUND

• Ujjan ID, Khan S, Nigar R, Ahmed H, Ahmad S, Khan A. The possible therapeutic role of curcumin and quercetin in the early-stage of COVID-19-Results from a pragmatic randomized clinical trial. Front Nutr. 2023 Jan 18;9:1023997. doi: 10.3389/fnut.2022.1023997. eCollection 2022.

  PMID: 36742008 BACKGROUND

MeSH Terms

Conditions

Post-Acute COVID-19 Syndrome

Interventions

Quercetin

Condition Hierarchy (Ancestors)

COVID-19; Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Post-Infectious Disorders; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Flavonols; Flavonoids; Chromones; Benzopyrans; Pyrans; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Masking Details: None (Open Label) (Participants and researchers will be aware of the treatment)
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Clinical Biochemistry and Experimental medicine

Model Details: This is a pragmatic, open-label clinical study evaluating the benefits of a combined quercetin/curcumin supplement (Nasafytol®) in adults experiencing mild to moderate Long COVID-19 symptoms.

Study Record Dates

• First Submitted: May 12, 2025
• First Posted: May 15, 2025
• Study Start: July 22, 2025
• Primary Completion: November 18, 2025
• Study Completion: December 14, 2025
• Last Updated: December 19, 2025

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

PA (1)